Press release                                                                                                                                               Ecully, 28 October 2019

 

Patent issued in the USA for the Mont-Blanc MIS range

 

Spineway, specialist in surgical implants and instruments for treating disorders of the spinal column (spine), has just been granted a new patent for its innovative Mont-Blanc MIS range in the USA.

The United States Patent and Trademark Office (USPTO) has issued Spineway a new patent for its minimally invasive surgery technology, Mont-Blanc MIS.

Launched at the end of 2016, the Mont-Blanc MIS range is currently the second best-selling range of the Group. This range offers surgeons unique technical features that make the surgical procedure more efficient but also safer in way to improve the treatment of severe pathologies of the spine.

With 15% of its turnover devoted to research and development, Spineway confirms its ability to market innovative products in the spine surgery sector.

 

SPINEWAY IS ELIGIBLE FOR THE PEA-PME (EQUITY SAVINGS PLANS FOR SMES)

Find out all about Spineway at www.spineway.com

 

Next communication: Turn over Q3 2019 and 2019 half-year results – 29 October 2019

 

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.
Spineway has an international network of over 50 independent distributors and 90% of its revenue comes from exports.
Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), has received the OSEO Excellence award since 2011 and has won the Deloitte Fast 50 award (2011). Rhône Alpes INPI Patent Innovation award (2013) – INPI Talent award (2015).
ISIN: FR0011398874 - ALSPW              

Contacts:

Spineway

Shareholder-services line
Available Tuesday through Thursday
(10 a.m. – 12 p.m.)
+33 (0)811 045 555

 
 Aelium

Finance et Communication

Investor relations
Solène Kennis
spineway@aelium.fr

 

Attachment